Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: BIIB VRTX BMRN ALNY SRPT NBIX ACAD SAGE RARE CYTK

| Held by: VTI IWM VXF IBB IWO XPH SCHA VTWO IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	16.57%	Shs Outstand	109.77M	Perf Week	1.00%
Market Cap	1.55B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-2.43%	Shs Float	91.63M	Perf Month	0.36%
Enterprise Value	1.21B	PEG	-	EPS next Q	-0.35	Inst Own	96.04%	Short Float	15.01%	Perf Quarter	14.52%
Income	-149.28M	P/S	-	EPS this Y	65.00%	Inst Trans	25.40%	Short Ratio	9.02	Perf Half Y	67.90%
Sales	-0.67M	P/B	4.67	EPS next Y	23.60%	ROA	-48.67%	Short Interest	13.75M	Perf YTD	16.89%
Book/sh	3.02	P/C	4.51	EPS next 5Y	33.70%	ROE	-56.52%	52W High	17.49 -19.27%	Perf Year	293.31%
Cash/sh	3.13	P/FCF	-	EPS past 3/5Y	-42.83% -78.71%	ROIC	-44.30%	52W Low	2.60 443.08%	Perf 3Y	-60.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	574.28% 127.75%	Gross Margin	186.77%	Volatility	5.52% 7.41%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	52.85%	Oper. Margin	23660.30%	ATR (14)	0.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.70	Sales Y/Y TTM	-100.34%	Profit Margin	22448.42%	RSI (14)	50.16	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	13.70	EPS Q/Q	65.50%	SMA20	-4.45%	Beta	-0.28	Target Price	21.11
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	4.73%	Rel Volume	0.41	Prev Close	14.07
Employees	123	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	33.85%	Avg Volume	1.52M	Price	14.12
IPO	Jan 07, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.10% -100.00%	Trades		Volume	621,275	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$10
Jun-24-25	Initiated	Guggenheim	Buy	$17
Jun-17-25	Initiated	Citigroup	Buy	$12
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform	$7
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Jan-29-26 05:05PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Jan-19-26 08:01AM	Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders (Insider Monkey)
Jan-10-26 02:57PM	Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases (Insider Monkey)
Jan-09-26 07:16AM	Amylyx selects AMX0318 as development candidate for PBH (TipRanks)
Jan-08-26 07:00AM	Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S (Business Wire)
04:35AM	Loading…
Dec-12-25 04:35AM	Amylyx pins its next hopes on a niche drug in the obesity space (Pharma Voice)
Dec-05-25 09:00AM	Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial (Business Wire)
Nov-28-25 06:40PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-10-25 09:40AM	Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-06-25 02:12PM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.89%
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 09:00AM	Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Oct-30-25 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-27-25 12:20PM	Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-26-25 06:16AM	BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet (Insider Monkey)
12:00PM	Loading…
Oct-24-25 12:00PM	What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
09:40AM	Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year? (Zacks)
Oct-16-25 04:43PM	Is AMLX Stock a Solid Choice Right Now? (Zacks)
Sep-10-25 12:06AM	Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock (Business Wire) +12.56%
Sep-09-25 04:01PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Aug-27-25 12:35PM	Amylyx culls rare neurological disorder programme after trial failure (Pharmaceutical Technology)
12:24PM	Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial (Benzinga)
07:22AM	Amylyx drug comes up short; Sanofi names new CMO (BioPharma Dive)
07:00AM	Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) (Business Wire)
Aug-19-25 12:07AM	H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) (Insider Monkey)
Aug-07-25 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-15-25 08:58AM	Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion (Insider Monkey)
Jul-14-25 11:52AM	Amylyx presents new exploratory analyses from avexitide trials for PBH (Clinical Trials Arena) +9.51%
05:00PM	Loading…
Jul-13-25 05:00PM	Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 (Business Wire)
Jul-08-25 07:00AM	Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 (Business Wire)
Jun-27-25 07:56AM	Why Shares in Amylyx Pharmaceuticals Soared This Week (Motley Fool)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-24-25 12:46PM	Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 (Insider Monkey) +27.69%
Jun-03-25 07:00AM	Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
May-21-25 07:00AM	Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 09:55AM	Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
May-12-25 07:00AM	Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome (Business Wire)
May-09-25 03:12AM	Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-08-25 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results (Business Wire) -5.95%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
08:00AM	Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences (Business Wire)
May-01-25 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
06:06AM	Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment (Clinical Trials Arena)
Apr-30-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRATES JAMES M	Chief Financial Officer	Feb 02 '26	Sale	14.65	3,557	52,097	173,547	Feb 04 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 02 '26	Sale	14.68	15,500	227,593	3,363,965	Feb 04 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 02 '26	Sale	14.65	3,448	50,516	144,693	Feb 04 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 02 '26	Sale	14.69	15,500	227,618	3,363,898	Feb 04 04:05 PM
Klee Justin B.	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,617		Feb 02 04:10 PM
Cohen Joshua B	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,593		Feb 02 04:10 PM
Mazzariello Gina	Officer	Feb 02 '26	Proposed Sale	14.65	3,448	50,515		Feb 02 04:10 PM
Frates James M	Officer	Feb 02 '26	Proposed Sale	14.65	3,557	52,097		Feb 02 04:10 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,182	1,492,668	3,514,814	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,818	21,332	3,381,439	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Sale	13.59	136,193	1,850,795	3,378,621	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Sale	13.83	1,974	27,299	3,379,465	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,153	1,492,448	3,514,739	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,847	21,552	3,381,393	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Sale	13.58	136,193	1,849,869	3,378,546	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Sale	13.89	1,995	27,701	3,379,398	Jan 20 09:46 PM
JUSTIN KLEE	Director	Jan 16 '26	Proposed Sale	13.52	1,995	26,972		Jan 16 04:05 PM
JOSHUA COHEN	Director	Jan 16 '26	Proposed Sale	13.52	1,974	26,688		Jan 16 04:03 PM
JOSHUA COHEN	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:17 PM
JUSTIN KLEE	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:14 PM
FRATES JAMES M	Chief Financial Officer	Jan 06 '26	Sale	11.11	3,326	36,954	177,104	Jan 08 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,596	3,317,632	Jan 08 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,589	3,317,586	Jan 08 04:05 PM
Frates James M	Officer	Jan 06 '26	Proposed Sale	11.11	3,326	36,954		Jan 06 04:05 PM
Klee Justin B.	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,590		Jan 06 04:05 PM
Cohen Joshua B	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,597		Jan 06 04:04 PM
Firestone Karen	Director	Dec 23 '25	Buy	12.45	8,100	100,845	63,100	Dec 23 08:48 PM
Bedrosian Camille L	Chief Medical Officer	Dec 01 '25	Sale	14.35	6,580	94,418	175,756	Dec 03 04:39 PM
Bedrosian Camille L	Officer	Dec 01 '25	Proposed Sale	14.35	6,580	94,419		Dec 01 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '25	Sale	14.38	29,975	430,952	3,325,301	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '25	Sale	14.58	8,828	128,669	148,141	Oct 02 04:15 PM
FRATES JAMES M	Chief Financial Officer	Sep 30 '25	Sale	14.65	10,558	154,650	280,430	Oct 02 04:15 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '25	Sale	14.35	29,933	429,469	3,325,347	Oct 02 04:15 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '25	Sale	14.58	12,039	175,518	182,336	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 13 '25	Sale	8.34	15,000	125,046	156,969	Aug 14 04:20 PM
Mazzariello Gina	Chief Legal Officer	Aug 12 '25	Sale	8.07	15,000	121,102	171,969	Aug 14 04:20 PM
GINA MAZZARIELLO	Officer	Aug 12 '25	Proposed Sale	7.82	30,000	234,600		Aug 12 04:25 PM
FRATES JAMES M	Chief Financial Officer	Mar 31 '25	Sale	3.47	10,896	37,806	290,988	Apr 02 05:22 PM
Bedrosian Camille L	Chief Medical Officer	Mar 31 '25	Sale	3.47	12,425	43,082	194,375	Apr 02 05:14 PM
Mazzariello Gina	Chief Legal Officer	Mar 31 '25	Sale	3.48	9,192	31,954	187,969	Apr 02 05:12 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 31 '25	Sale	3.47	21,490	74,482	3,355,280	Apr 02 04:57 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 31 '25	Sale	3.46	21,490	74,454	3,355,276	Apr 02 04:52 PM
Zeiher Bernhardt G	Director	Mar 20 '25	Buy	3.70	10,000	37,005	10,000	Mar 24 04:15 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 03 '25	Sale	3.15	4,595	14,483	3,196,648	Mar 05 04:35 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 03 '25	Sale	3.17	4,595	14,549	3,196,652	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Mar 03 '25	Sale	3.12	1,611	5,022	133,310	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Feb 24 '25	Sale	3.15	4,169	13,145	134,921	Feb 26 04:35 PM

Open in Screener

AUPH

Aurinia Pharmaceuticals Inc

Feb 13 • 04:00PM ET

14.23

-0.08 -0.56 %

Healthcare • Biotechnology • Canada • NASD

AUPH Aurinia Pharmaceuticals Inc daily Stock Chart

Peers: AMGN REGN VRTX ABBV GILD BIIB BMRN INCY SAGE NBIX

| Held by: IWM IWO IBB VTWO JSMD VHT FESM AVSC BRNY JSML

Index	RUT	P/E	25.36	EPS (ttm)	0.56	Insider Own	11.91%	Shs Outstand	131.84M	Perf Week	-1.45%
Market Cap	1.88B	Forward P/E	15.22	EPS next Y	0.94	Insider Trans	0.00%	Shs Float	116.14M	Perf Month	-6.57%
Enterprise Value	1.60B	PEG	0.08	EPS next Q	0.22	Inst Own	53.75%	Short Float	7.89%	Perf Quarter	-8.43%
Income	77.84M	P/S	7.06	EPS this Y	1854.17%	Inst Trans	5.33%	Short Ratio	7.66	Perf Half Y	17.70%
Sales	265.81M	P/B	5.13	EPS next Y	19.62%	ROA	14.46%	Short Interest	9.16M	Perf YTD	-10.78%
Book/sh	2.77	P/C	5.33	EPS next 5Y	197.20%	ROE	20.65%	52W High	16.54 -13.97%	Perf Year	78.54%
Cash/sh	2.67	P/FCF	15.58	EPS past 3/5Y	- -	ROIC	18.25%	52W Low	6.55 117.25%	Perf 3Y	75.25%
Dividend Est.	-	EV/EBITDA	13.75	Sales past 3/5Y	72.76% 274.78%	Gross Margin	88.93%	Volatility	2.57% 3.05%	Perf 5Y	-9.71%
Dividend TTM	-	EV/Sales	6.03	EPS Y/Y TTM	469.63%	Oper. Margin	36.53%	ATR (14)	0.46	Perf 10Y	529.65%
Dividend Ex-Date	-	Quick Ratio	5.17	Sales Y/Y TTM	20.62%	Profit Margin	29.28%	RSI (14)	38.94	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	5.76	EPS Q/Q	135.53%	SMA20	-2.76%	Beta	1.54	Target Price	16.71
Payout	0.00%	Debt/Eq	0.21	Sales Q/Q	8.41%	SMA50	-6.63%	Rel Volume	0.49	Prev Close	14.31
Employees	130	LT Debt/Eq	0.17	Earnings	Nov 04 BMO	SMA200	18.94%	Avg Volume	1.20M	Price	14.23
IPO	Oct 20, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.75% 8.51%	Trades		Volume	584,630	Change	-0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$16
Nov-07-25	Upgrade	Jefferies	Hold → Buy	$21
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15
Jul-30-25	Resumed	H.C. Wainwright	Buy	$17
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11

Show Previous Ratings

Feb-11-26 05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
Feb-06-26 02:03PM	This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Dec-26-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-10-25 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
12:00PM	Loading…
Dec-05-25 12:00PM	What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-02-25 10:15AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Nov-27-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-24-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-07-25 12:20PM	Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ... (GuruFocus.com) +8.35%
07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:11AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Loading…
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress (Business Wire)
Nov-03-25 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 (Business Wire)
05:00AM	Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark (BioPharma Dive)
04:49AM	Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir (The Wall Street Journal)
Nov-02-25 07:59PM	FDA Official Steps Down, Sued by Drugmaker (The Wall Street Journal)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-15-25 06:00AM	Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 (Business Wire)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 08:27PM	Aurinia Responds to Now Retracted LinkedIn Post (Business Wire) -15.83%
03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
01:57PM	Loading…
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-04-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know (Zacks) +9.15%
Aug-01-25 05:01AM	Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +13.47%
Jul-31-25 07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
06:13AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 (Business Wire)
Jul-22-25 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 (Business Wire)
Jul-02-25 08:48AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Jun-30-25 06:00AM	Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) (Business Wire)
Jun-29-25 05:00PM	Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 (Business Wire)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
May-30-25 08:46AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
May-22-25 06:00AM	New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis (Business Wire)
May-13-25 09:24AM	Company News for May 13, 2025 (Zacks)
03:03AM	Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:07AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (Business Wire)
May-05-25 06:00AM	Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 (Business Wire)
Apr-30-25 06:00AM	Glass Lewis Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-29-25 06:00AM	ISS Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-26-25 10:54AM	Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (Seeking Alpha)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 04:05PM	Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting (Business Wire)
09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
Mar-25-25 10:41AM	Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-07-25 04:47PM	Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-25 01:14PM	Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
Feb-28-25 02:13AM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.30%
Feb-27-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates (Zacks) -5.03%
06:28AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Business Wire)
Feb-25-25 12:31PM	Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-20-25 04:05PM	Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 (Business Wire)
Jan-22-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's Why (Zacks)
Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)
Nov-14-24 06:00AM	Aurinia to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 10:30AM	Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets (Pharmaceutical Technology)
06:37AM	Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring (TipRanks)
02:12AM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 07:40AM	Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates (Zacks) +10.90%
06:41AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:10AM	Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Business Wire)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development (Business Wire)
Oct-30-24 04:05PM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Business Wire)
06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-11-24 06:00AM	Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 (Business Wire)
Sep-24-24 08:10AM	Aurinia Announces Japan Approval of LUPKYNIS (Voclosporin) to Treat Lupus Nephritis (Business Wire)
Sep-13-24 06:00AM	Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference (Business Wire) +6.84%
Sep-12-24 07:02PM	Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc (GuruFocus.com)
04:05PM	Aurinia Announces Board Restructuring (Business Wire)
Sep-06-24 06:32AM	Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases (Clinical Trials Arena) +5.07%
Sep-05-24 06:00AM	Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Business Wire)
Aug-28-24 06:00AM	Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-22-24 10:09AM	Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't? (Zacks)
Aug-13-24 08:00AM	Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board (Business Wire)
Aug-01-24 07:10AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:14AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Business Wire)
Jul-19-24 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 (Business Wire)
Jul-12-24 04:39AM	Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-24 03:27PM	ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM (Business Wire) +6.55%
Jul-02-24 06:00AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Jun-17-24 04:46AM	Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Jun-14-24 12:16PM	Aurinia Announces 2024 Annual General Meeting Results (Business Wire) +5.61%

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TANG KEVIN	Director	Aug 01 '25	Buy	10.12	1,000,000	10,120,000	11,029,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 05 '25	Buy	11.68	200,000	2,336,000	11,329,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 04 '25	Buy	11.34	100,000	1,134,000	11,129,500	Aug 05 05:31 PM
Keenan Greg	Chief Medical Officer	Aug 01 '25	Sale	10.50	20,000	210,000	133,484	Aug 05 04:07 PM
Keenan Greg	Chief Medical Officer	Mar 07 '25	Sale	8.23	8,305	68,350	153,484	Mar 07 05:25 PM
Greenleaf Peter	Chief Executive Officer	Mar 03 '25	Sale	8.00	195,593	1,564,744	1,953,892	Mar 04 09:02 PM
Greenleaf Peter	Chief Executive Officer	Mar 04 '25	Sale	7.92	164,947	1,306,380	1,788,945	Mar 04 09:02 PM
Keenan Greg	Chief Medical Officer	Mar 03 '25	Sale	8.00	12,239	97,912	161,789	Mar 04 08:59 PM
Miller Joseph M	Chief Financial Officer	Mar 03 '25	Sale	8.00	61,859	494,872	633,515	Mar 04 08:58 PM
Miller Joseph M	Chief Financial Officer	Mar 04 '25	Sale	7.92	56,154	444,740	577,361	Mar 04 08:58 PM
Robertson Stephen P.	EVP, General Counsel	Mar 03 '25	Sale	8.00	64,872	518,976	566,883	Mar 04 08:57 PM
Robertson Stephen P.	EVP, General Counsel	Mar 04 '25	Sale	7.92	57,607	456,247	509,276	Mar 04 08:57 PM
Donley Matthew Maxwell	Chief Operating Officer	Mar 03 '25	Sale	8.00	65,902	527,216	739,456	Mar 04 08:56 PM
Donley Matthew Maxwell	Chief Operating Officer	Mar 04 '25	Sale	7.92	58,991	467,209	680,465	Mar 04 08:56 PM
TANG KEVIN	Director	Mar 04 '25	Buy	7.96	748,038	5,953,304	10,029,500	Mar 04 05:03 PM
TANG KEVIN	Director	Mar 03 '25	Buy	8.01	452,682	3,625,474	9,281,462	Mar 04 05:03 PM
TANG KEVIN	Director	Feb 28 '25	Buy	7.85	399,280	3,134,348	8,828,780	Mar 04 05:03 PM

AMLX

Amylyx Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your FINVIZ experience